Seminal
The magazine and atlas of EU-funded researchA new publication from the web and AI team at Scott Charnley

Atlas / Belgium

European Research Council grant · Running

My-NANO Advancing NANOmedicines to rewire tumoral MYeloid cells for next-generation cancer immunotherapies

Coordinator
Universiteit Gent, Belgium
Runs
1 May 2026 to 30 April 2031
Status
Running
EU funding
€2.5m
Total cost
€2.5m
Partners
1 organisations in 1 countries
Type
European Research Council grant
Grant agreement
101230424

What the project is doing

In the project's own words, from its summary on CORDIS.

Persistent inflammation during tumorigenesis drives myelopoiesis. Consequently, monocytes and granulocytes/neutrophils infiltrate the tumor microenvironment (TME) and differentiate into tumor-associated macrophages or myeloid-derived suppressor cells, creating an immune-suppressive microenvironment that hampers cytotoxic T cell function and limits immune checkpoint inhibitor (ICI) efficacy. ‘Reprogramming’ myeloid cells to adopt pro-inflammatory phenotypes is promising to restore immune function and enhance ICI responses.

Lipid nanoparticles (LNPs) have emerged as a delivery platform for nucleic acids, as demonstrated by the mRNA-LNP COVID vaccines. Pioneering studies revealed that myeloid cells are robustly recruited to the vaccine injection site where they internalize mRNA-LNPs, leading to mRNA expression in monocytes. While nanoparticle (NP) transport into inflamed tissues and tumors has been attributed to ‘enhanced permeation/retention’ of the NPs, my recent findings, in an inflamed arthritis model, highlight a critical role of circulating myeloid cells in the active transport of intravenously injected LNPs.

Therefore, I hypothesize that mRNA-LNPs can transfect tumor-infiltrating myeloid cells reversing immune-suppression. My-NANO will study interactions between myeloid cells and lipid-based NPs through the following objectives: (1) elucidating the role of myeloid cells in the transport of lipid-based NPs to tumors (WP1), (2) investigating how mRNA-LNPs influence innate immune responses/phenotype switches in myeloid cells (WP2) and (3) optimizing mRNA-LNP design for efficient/selective mRNA expression in myeloid cells (WP3).

Based on this knowledge My-NANO will design mRNA-LNPs to restore the phagocytic function of myeloid cells by knocking out SIRP-1α or by generating CAR-macrophages to enhance tumor responses to ICIs (WP4). By employing state-of-the-art methodologies, My-NANO hopes to advance mRNA-LNPs as ‘myeloid cell therapeutics’ for cancer immunotherapy.

Topics

Who is involved

OrganisationCityCountryRole
Universiteit GentGentBelgiumCoordinator

Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI